Anthem Biosciences · NSE: ANTHEM · BSE: 544449
Q4 FY26 results · Jan–Mar 2026
Anthem Biosciences reported revenue from operations of ₹610.94 crore and net profit of ₹189.76 crore for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 610.94 | — | — | 423.15 | +44.4% |
| Other income | 51.21 | — | — | 33.53 | +52.7% |
| Total income | 662.15 | — | — | 456.68 | +45.0% |
| Profit before tax | 277.92 | — | — | 130.47 | +113.0% |
| Net profit for the period | 189.76 | — | — | 92.82 | +104.4% |
| EPS, basic (₹) | 3.38 | — | — | 1.65 | +104.8% |
| Net margin (%) | 31.1 | — | 21.9 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 582.50 | — | — | 416.57 | +39.8% |
| Other income | 60.62 | — | — | 39.92 | +51.9% |
| Total income | 643.13 | — | — | 456.50 | +40.9% |
| Profit before tax | 300.72 | — | — | 150.11 | +100.3% |
| Net profit for the period | 211.66 | — | — | 112.12 | +88.8% |
| EPS, basic (₹) | 3.77 | — | — | 2.00 | +88.5% |
| Net margin (%) | 36.3 | — | 26.9 |
Consolidated
- Filed with BSE
- 20 May 2026, 00:11 IST
- Board meeting
- 19 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 May 2026, 00:11 IST
- Board meeting
- 19 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE